Publications

Show Filters

Searches all publications.

Search Term

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-06-24
    E.g., 2018-06-24

Articles

257318 items
12:00 AM, Apr 10, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Vertex Pharmaceuticals Inc. (VRTX) David Stone of Cowen & Co. said the publication in Nature of a Merck paper on HIV resistance to protease inhibitors is old news and shouldn't be viewed negatively (see page...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Other News

Pfizer other research news

Pfizer (Groton, Conn.) published its use of the GLUT4 receptor as a gene therapy in mice, reporting in the Journal of Clinical Investigation that the strategy boosted insulin responsiveness and corrected blood glucose levels in...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Tularik deal

Tularik Inc.   Privately held Tularik and Taisho Pharmaceutical Co. Ltd. (Tokyo) will develop small molecule therapeutics for a variety of immune system disorders.   The companies will develop drugs capable of modulating the...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Clinical News  |  Clinical Results

Batimastat matrix metalloproteinase inhibitor data

BBIOY (Oxford, U.K.) announced early results of a Phase I/II trial showing that patients reaccumulated pleural fluid more slowly after being given the agent, and that the drug was well tolerated. As reported at...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Human Genome Sciences deal

As amended, HGSI may submit to SmithKline four special therapeutic protein proposals per quarter, and will have exclusive rights to develop or outlicense a maximum of six of the designated proteins per year, for use...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Other News

Icos other research news

ICOS and university collaborators reported the cloning and expression of the human gene for platelet activating factor acetylhydrolase, an enzyme that breaks down platelet activating factor, an inflammatory mediator. As published in Nature, the...
12:00 AM, Apr 10, 1995  |  BC Week In Review | Company News  |  Deals

Biovail Corp. International deal

BVF reacquired the U.S. rights to its once-daily controlled release formulation of Diltiazem HCI from Hoechst-Roussel Pharmaceuticals Inc. The Toronto company said it decided to reacquire the product after Hoechst announced it would acquire controlling...
12:00 AM, Apr 10, 1995  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Neozyme II (NIIUF) Michael Ehrenreich of Ehrenreich & Co. lowered his rating on NIIUF from "overweight" to "market weight." He said the shares of the special purpose financing vehicle, formed by Genzyme Corp. to...
12:00 AM, Apr 10, 1995  |  BioCentury | Strategy

Calgene's Transwitch license

In a further tightening of the technology ties between agricultural biotechnology companies, Calgene Inc. purchased for an undisclosed amount an option for a non-exclusive license to DNA Plant Technology Corp.'s Transwitch technology. CGNE's option is for...
12:00 AM, Apr 10, 1995  |  BioCentury | Strategy

DNAP adds to Calgene's license portfolio

In a further tightening of the technology ties between agricultural biotechnology companies, Calgene Inc. purchased for an undisclosed amount an option for a non-exclusive license to DNA Plant Technology Corp.'s Transwitch technology. CGNE's option is for...

Pages